Among these, liraglutide in the LEADER study, semaglutide in the SUSTAIN-6, albiglutide in the Harmony Outcomes, dulaglutide in the REWIND, and efpeglenatide in the AMPLITUDE-O exhibited significant beneficial effects on 3-point major adverse cardiac events (3P-MACE: death from CV disease, non-fatal myocardial infarction, and non-fatal stroke), the primary end point of each study, compared to the placebo group, respectively
Key takeaway: GLP-1 medications like tirzepatide and semaglutide can affect the menstrual cycle, typically due to hormonal shifts related to rapid weight loss and metabolic changes
Safety considerations: GLP-1 receptor agonists are contraindicated in patients with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2
This is perfectly acceptable for vials you plan to reconstitute within the next year
Lee and Jun 2016)
And heres what I know: Trumps $150 plan cant help people like me